Skip to content

The toxicology and characteristics of fatal new psychoactive stimulant and hallucinogen-related poisonings in Australia, 2000–2025

Shane Darke, Johan Duflou, Michael Farrell, Julia Lappin, Amy Peacock

Drug and Alcohol Dependence Reports March 22, 2026 DOI: 10.1016/j.dadr.2026.100434 via OpenAlex

Summary

AI-generated from the abstract

From 2000 to 2025, 70 fatal poisonings involving new psychoactive stimulants and hallucinogens (NPSH) were identified in Australia, the first occurring in 2007. In nearly a quarter of cases, the person appeared unaware they were consuming an NPSH, and about a third involved injection. Common signs of acute poisoning included intense agitation, sudden collapse, and hyperthermia. Cathinones were the most frequently detected NPSH, followed by phenethylamines and tryptamines. Over a quarter of cases had multiple NPSH in the blood. In the 2020s, tryptamines became more common while phenethylamines became less common, and a wider range of NPSH were detected. Psychoactive drugs besides NPSH were present in most cases, especially psychostimulants and hypnosedatives.

Study at a glance

Characteristics Retrospective study Peer reviewed
Sample size 70
Population Fatal NPSH-related poisoning cases in Australia
Duration 2000-2025
Keywords Stimulant Poison control Psychoactive drug Medicine Toxicology
Key finding A wider range of NPSH have been detected in recent fatal poisonings, with tryptamines becoming more common in the 2020s and phenethylamines less common.

Abstract

New psychoactive stimulants and hallucinogens (NPSH) poisonings have generated considerable public health concern in recent years. We aimed to determine: 1. The characteristics, toxicology and major autopsy findings of known cases of NBZD-related poisoning in Australia, 2000-2025; and 2. Changes in characteristics of known cases from 2020 onwards compared to earlier known cases. Retrospective study of fatal NPSH-related poisonings in Australia retrieved from the National Coronial Information System. 70 cases were identified, the first occurring in 2007. In 22.9% the decedent appeared unaware they were consuming a NPHS, and in 32.9% the NPSH had been injected. The most commonly observed signs and symptoms of acute NPSH poisoning were intense agitation (22.9%), sudden collapse (22.9%) and hyperthermia (20.0%). There were 31 NPSH identified, of which 13 were first detected in the 2020 s. The most commonly detected NPSH were cathinones (48.6%), most frequently α-pyrrolidinovalerophenone and methylenedioxypyrovalerone. Phenethylamines were present in 38.6%, with paramethoxymethamphetamine and a range of the N-benzylphenethylamine series ( NBOMe) the most common. Tryptamines were present in 18.6%, and three cases involved piperazines. In 18 cases (25.7%) multiple NPSH were detected in the blood. 2020 s cases were more likely to have tryptamines detected (36.7 v 5.0%), but less likely to have phenethylamines (23.3 v 50.0%). Psychoactive drugs in addition to NPSH were present in 92.9%, most commonly psychostimulants (68.6%) and hypnosedatives (40.0%). A wider range of NPHS have been detected in recent fatal poisonings, with tryptamines becoming more common in the 2020 s, and phenethylamines less common. • 70 fatal toxicity cases involving new psychoactive stimulants/hallucinogens (NPSH) • 31 NPSH identified, of which 13 were first detected in the 2020 s • The most commonly detected NPSH were cathinones (48.6%) • In 18 cases (25.7%) multiple NPSH were detected in the blood • In 16 cases the decedent appeared unaware they were consuming a NPHS

Comments

No comments yet.

Log in to comment